High Heights Biotechnology has been appointed as the official business development partner for the international launch of HelioLiver™ early detection cancer testing by Helio Genomics. With a shared commitment to improving healthcare outcomes, we are dedicated to expanding access to this ground-breaking technology and fostering collaborative partnerships to introduce HelioLiver™to healthcare providers and patients around the world.

QBID (Quality Brands International Direct) - an international brand representation business. Founded 2015 by G.Panagios and J. Kilborn, QBID's focussed on e-commerce in emerging markets especially China. QBID was the exclusive launch partner of JD.com in Australia, and QBID operated more than 20 brand flagship stores on JD, VIP, TMall and others. Provision of e-commerce stores and access, brand protection, in-market, online and traditional media promotion and China social media support, as well as logistics and supply chain management. More than 50 brand client-contracts were fulfilled 2015-2019, with international pharmaceutical, nutritional, food, health, beauty and skincare brands HQ’d in ANZ, Europe and USA. Business grew to >$10m in sales, and profitable, in the 1st 3 years. QBID was sold 2019 to RLG ASX.

Contract Manufacturing Manager for external customers of Nutrition Care Pharmaceuticals.

Co-founder and CEO of this medical devices startup focussed on development of a miniaturized, sub-cutaneous continuous glucose monitor for diabetes. Key responsibilities included development of business plan, refining ongoing IP strategy, selection of key team, identification of and development of relations with VC community to secure funding.

European Vice President, member of EMEA Management Committee, jointly responsible for $4.8 billion in sales and $1.8 billion in EBIT in 2004. CEO of the German, Swiss and Austrian pharmaceutical businesses with a turnover of USD720 million and 1050 employees

Director of Bristol-Myers Squibb Australia, with four divisions. Managing Director of Pharmaceutical Division with responsibility for 350 staff, $AUD 320 million revenue. Concurrently Board member and Vice Chairman Medicines Australia (national industry body), and Chair Health Economics Committee.

Responsible for $200m+ portfolio and >20 marketing professionals.